Methylprednisone    (DrugBank: Methylprednisone)

3 diseases
IDDisease name (Link within this page)Number of trials
46Malignant rheumatoid arthritis1
66IgA nephropathy1
222Primary nephrotic syndrome1

46. Malignant rheumatoid arthritis    [ 4,183 clinical trials,   2,538 drugs,   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways]
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 4,183 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00282308
(ClinicalTrials.gov)
January 23, 200624/1/2006A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background MethotrexateA Phase II, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background MethotrexateRheumatoid ArthritisDrug: Rituximab;Drug: Methotrexate;Drug: Methylprednisone;Biological: C. albicans;Biological: Tetanus toxoid adsorbed booster vaccine;Biological: 23-valent pneumococcal polysaccharide vaccine;Biological: Keyhole limpet hemocyaninGenentech, Inc.NULLCompleted18 Years65 YearsAll103Phase 2United States

66. IgA nephropathy    [ 199 clinical trials,   214 drugs,   (DrugBank: 57 drugs),   32 drug target genes,   128 drug target pathways]
Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 199 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00367562
(ClinicalTrials.gov)
January 199622/8/2006Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA NephropathyPhase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA NephropathyIGA NephropathyDrug: ENALAPRIL VALSARTAN METHYLPREDNISONEHospital BritanicoNULLCompleted21 Years70 YearsBoth20Phase 4Argentina

222. Primary nephrotic syndrome    [ 234 clinical trials,   241 drugs,   (DrugBank: 78 drugs),   59 drug target genes,   185 drug target pathways]
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 234 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02921789
(ClinicalTrials.gov)
May 22, 201730/9/2016Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant RecipientsA Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant RecipientsKidney Transplantation;Focal Segmental Glomerulosclerosis (FSGS)Drug: Bleselumab;Drug: Basiliximab;Drug: Mycophenolate Mofetil (MMF);Drug: Tacrolimus Capsules;Drug: Methylprednisone;Drug: PrednisoneAstellas Pharma Global Development, Inc.Kyowa Kirin Co., Ltd.Recruiting18 YearsN/AAll60Phase 2United States;Canada